DK0565587T3 - Virkning af N,N,N-trimethylsphingosin på proteinkinase-C-aktivitet, melanomcellevækst in vitro, metastatisk potentiale in vivo og human blodpladeaggregation. - Google Patents

Virkning af N,N,N-trimethylsphingosin på proteinkinase-C-aktivitet, melanomcellevækst in vitro, metastatisk potentiale in vivo og human blodpladeaggregation.

Info

Publication number
DK0565587T3
DK0565587T3 DK92902672.2T DK92902672T DK0565587T3 DK 0565587 T3 DK0565587 T3 DK 0565587T3 DK 92902672 T DK92902672 T DK 92902672T DK 0565587 T3 DK0565587 T3 DK 0565587T3
Authority
DK
Denmark
Prior art keywords
pct
trimethylsphingosine
platelet aggregation
activity
effect
Prior art date
Application number
DK92902672.2T
Other languages
English (en)
Inventor
Satoshi Kimura
Yasyuki Igarashi
Sen-Itiroh Hakomori
Mahammed N Ahmad
Hirofumi Okoshi
Kazuko Handa
Original Assignee
Oncomembrane Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/636,353 external-priority patent/US5137919A/en
Application filed by Oncomembrane Inc filed Critical Oncomembrane Inc
Application granted granted Critical
Publication of DK0565587T3 publication Critical patent/DK0565587T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK92902672.2T 1990-12-31 1991-12-23 Virkning af N,N,N-trimethylsphingosin på proteinkinase-C-aktivitet, melanomcellevækst in vitro, metastatisk potentiale in vivo og human blodpladeaggregation. DK0565587T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/636,353 US5137919A (en) 1990-12-31 1990-12-31 Effect of N,N,N,-trimethylsphingosine on protein kinase C activity melanoma cell growth in vitro; metastatic potential in vivo and human platelet aggregation
US07/724,625 US5151360A (en) 1990-12-31 1991-07-02 Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation

Publications (1)

Publication Number Publication Date
DK0565587T3 true DK0565587T3 (da) 1997-09-22

Family

ID=27092583

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92902672.2T DK0565587T3 (da) 1990-12-31 1991-12-23 Virkning af N,N,N-trimethylsphingosin på proteinkinase-C-aktivitet, melanomcellevækst in vitro, metastatisk potentiale in vivo og human blodpladeaggregation.

Country Status (10)

Country Link
US (2) US5151360A (da)
EP (1) EP0565587B1 (da)
JP (1) JPH06504052A (da)
AT (1) ATE150000T1 (da)
CA (1) CA2097324A1 (da)
DE (1) DE69125185T2 (da)
DK (1) DK0565587T3 (da)
ES (1) ES2100333T3 (da)
GR (1) GR3023511T3 (da)
WO (1) WO1992012119A1 (da)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583160A (en) * 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
US5466716A (en) * 1990-12-31 1995-11-14 The Biomembrane Institute Liposomal trimethylsphingosine
ES2194013T3 (es) * 1992-05-29 2003-11-16 Univ North Carolina Plaquetas de sangre humana de secado fijo farmaceuticamente aceptables.
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
USRE39300E1 (en) 1993-01-28 2006-09-19 Virginia Commonwealth University Medical College Of Virginia Inhibiting the development of tolerance to and/or dependence on an addictive substance
DE69410814T2 (de) * 1993-10-18 1998-11-12 Virginia Tech Intell Prop Synthese von sphingosinen
CA2187167A1 (en) * 1994-04-04 1995-10-12 Samuel Davis Biologically active eph family ligands
US5627171A (en) * 1994-04-11 1997-05-06 Oncomembrane, Inc. Sphingosine-1-phosphate/trimethylsphingosine composition
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
EP0754053A1 (en) * 1995-02-03 1997-01-22 Korea Institute of Science and Technology Novel hemostatic composition
WO1997030174A1 (en) * 1996-02-20 1997-08-21 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers
GB9620390D0 (en) * 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
WO1998055602A1 (en) * 1997-06-06 1998-12-10 Mayo Foundation For Medical Education And Research Screening for phosphatidylinositol related-kinase inhibitors
US6649362B2 (en) * 1997-09-08 2003-11-18 Medvet Science Pty. Ltd. Screening method for an agent having an effect on a sphingosine kinase signaling pathway
US6098631A (en) * 1998-01-21 2000-08-08 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disease
AU2001234978A1 (en) 2000-02-10 2001-08-20 The Regents Of The University Of California Therapeutic platelets and methods
US6770478B2 (en) 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
US20030028018A1 (en) * 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
ATE309996T1 (de) * 2000-09-11 2005-12-15 Chiron Corp Chinolinonderivate als tyrosin-kinase inhibitoren
EP1363643A2 (en) * 2000-12-22 2003-11-26 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
WO2003086377A1 (fr) * 2002-04-18 2003-10-23 Institute Of Medicinal Molecular Design. Inc. Derives amide
CA2486106C (en) 2002-05-16 2013-07-16 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function
JP2006502986A (ja) * 2002-07-03 2006-01-26 グリコミメティクス， インコーポレイテッド 新脈管形成に関与する医学的状態の診断および治療のための組成物および方法
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
EP1539754A4 (en) * 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOLE QUINOLINONES AND USES THEREOF
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
WO2004043389A2 (en) * 2002-11-13 2004-05-27 Chiron Corporation Methods of treating cancer and related methods
US20040219158A1 (en) * 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
EP1692085A4 (en) * 2003-11-07 2010-10-13 Novartis Vaccines & Diagnostic INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA
JP2007524658A (ja) * 2003-11-19 2007-08-30 グリコミメティクス， インコーポレイテッド Ｅ−およびｐ−セレクチンの両方のための糖模倣物アンタゴニスト
WO2005051920A2 (en) * 2003-11-19 2005-06-09 Glycomimetics, Inc. Specific antagonist for both e- and p-selectins
CN1960731B (zh) * 2004-02-20 2011-12-07 诺华疫苗和诊断公司 调节炎性和转移过程的方法
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2006089168A2 (en) * 2005-02-18 2006-08-24 Cornell Research Foundation, Inc. Methods for modulating ion channels
JP5344910B2 (ja) 2005-05-13 2013-11-20 ノバルティス アーゲー 薬剤耐性癌の処置方法
WO2006127926A2 (en) * 2005-05-23 2006-11-30 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
WO2006127906A1 (en) * 2005-05-25 2006-11-30 Glycomimetics, Inc. Heterobifunctional compounds for selectin inhibition
AU2006280101B2 (en) * 2005-08-09 2012-06-28 Glycomimetics, Inc. Glycomimetic inhibitors of the PA-IL lectin, PA-IIL lectin or both the lectins from Pseudomonas
AU2006284578B2 (en) 2005-09-02 2011-01-27 Glycomimetics, Inc. Heterobifunctional pan-selectin inhibitors
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US9274129B2 (en) * 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US8796429B2 (en) * 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
US9217749B2 (en) * 2006-05-31 2015-12-22 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
WO2007143052A1 (en) * 2006-06-01 2007-12-13 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
JP5298020B2 (ja) * 2006-10-12 2013-09-25 グリコミメティクス， インコーポレイテッド ヘキソースおよびｎ−アセチルヘキソサミンの糖模倣体置換
SI2087002T1 (sl) 2006-10-27 2014-11-28 Lpath, Inc. Sestavki in postopki za vezavo sfingozin-1-fosfata
US8444970B2 (en) * 2006-10-27 2013-05-21 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
JP5511390B2 (ja) * 2007-02-09 2014-06-04 グリコミメティクス， インコーポレイテッド ヘキソースおよびｎ−アセチルヘキソサミンの置換体を有する糖模倣体の使用方法
DE102007008484A1 (de) * 2007-02-19 2008-08-21 Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh Pharmazeutische Zubereitung zur Bekämpfung von Metastasen
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
WO2009126556A1 (en) 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
ES2426784T3 (es) * 2008-06-13 2013-10-25 Glycomimetics, Inc. Tratamiento de cánceres de la sangre usando compuestos glicomiméticos seleccionados
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
CA2760292A1 (en) * 2009-05-01 2010-11-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
EP2462105A1 (en) * 2009-08-04 2012-06-13 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Amino-alcohol analogues and uses thereof
US8747844B2 (en) 2010-07-30 2014-06-10 Saint Louis University Methods of treating pain
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
JP2015500887A (ja) 2011-12-22 2015-01-08 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンアンタゴニスト化合物、組成物および使用方法
AU2013355238B2 (en) 2012-12-07 2017-12-14 Glycomimetics, Inc. Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
ES2851724T3 (es) 2013-09-18 2021-09-08 Epiaxis Therapeutics Pty Ltd Modulación de células madre
SI3227310T1 (sl) 2014-12-03 2019-11-29 Glycomimetics Inc Heterobifunkcionalni inhibitorji e-selektinov in receptorjev kemokina CXCR4
WO2017015334A1 (en) 2015-07-21 2017-01-26 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
CA3009836A1 (en) 2016-01-22 2017-07-27 Glycomimetics, Inc. Glycomimetic inhibitors of pa-il and pa-iil lectins
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
WO2018031445A1 (en) 2016-08-08 2018-02-15 Glycomimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4
JP7069136B2 (ja) 2016-10-07 2022-05-17 グリコミメティクス， インコーポレイテッド 極めて強力な多量体ｅ－セレクチンアンタゴニスト
EP3596096A1 (en) 2017-03-15 2020-01-22 GlycoMimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
JP7275131B2 (ja) 2017-11-30 2023-05-17 グリコミメティクス， インコーポレイテッド 骨髄浸潤リンパ球を動員する方法、およびその使用
CN111566117A (zh) 2017-12-29 2020-08-21 糖模拟物有限公司 E-选择蛋白和半乳凝素-3的异双功能抑制剂
JP7455064B2 (ja) 2018-03-05 2024-03-25 グリコミメティクス， インコーポレイテッド 急性骨髄性白血病および関連状態を処置する方法
WO2020139962A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3705384A1 (de) * 1987-02-20 1988-09-01 Goedecke Ag 2-propylamin-derivate, verfahren zu deren herstellung sowie deren verwendung
CA2007507C (en) * 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine and n-methyl-sphingosine as inhibitor of cell growth

Also Published As

Publication number Publication date
EP0565587B1 (en) 1997-03-12
US5331014A (en) 1994-07-19
EP0565587A1 (en) 1993-10-20
DE69125185T2 (de) 1997-08-28
JPH06504052A (ja) 1994-05-12
GR3023511T3 (en) 1997-08-29
EP0565587A4 (en) 1994-06-01
ATE150000T1 (de) 1997-03-15
WO1992012119A1 (en) 1992-07-23
DE69125185D1 (de) 1997-04-17
CA2097324A1 (en) 1992-07-01
ES2100333T3 (es) 1997-06-16
US5151360A (en) 1992-09-29

Similar Documents

Publication Publication Date Title
DK0565587T3 (da) Virkning af N,N,N-trimethylsphingosin på proteinkinase-C-aktivitet, melanomcellevækst in vitro, metastatisk potentiale in vivo og human blodpladeaggregation.
GEP20032954B (en) Heterocyclic Inhibitors of P38
FI962591A (fi) Kasvuhormonia vapauttavia ominaisuuksia sisältäviä yhdisteitä
IL133825A0 (en) Substituted 6-phenylphenanthridines, medicaments containing same and use thereof
TR199701355A2 (xx) L�kozit adhasyonu inhibit�rleri olarak yeni heterosiklenler ve vla-4-antagonistleri.
DE69326776T2 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
ATE296799T1 (de) P38-inhibitoren
DE69327536T2 (de) Fibrinogenrezeptor-antagonisten
YU13396A (sh) N-(3-benzofuranil) urea derivati, postupci za njihovo dobijanje, kompozicije koje ih sadrže i njihova upotreba u lekovima
BR9611175B1 (pt) compostos e composiÇÕes farmacÊuticas.
ES2173480T3 (es) Preparacion de derivados de ciclohexeno carboxilato.
SE9901875D0 (sv) Novel compounds
TR200200778T2 (tr) Pirazol türevleri.
IL81002A0 (en) Pyrazoline derivatives,processes for their preparation and pesticidal compositions containing the same
BG104899A (en) Antipicornaviral compounds and compositions, their pharmaceutical use and materials for their synthesis
YU47116B (sh) Postupak za dobijanje novih n-supstituisanih benzimidazolskih derivata
FR2712591B1 (fr) Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique.
BG96171A (bg) Амидинофенилаланинови производни,метод за получаването им, приложението им и средства,които ги съдържат
ATE273281T1 (de) Heterozyklische cytotoxische wirkstoffe
IL117209A (en) 1-aryl-2-acylamino-ethane compounds and pharmaceutical compositions containing them
ATE49749T1 (de) Aminosaeurederivate mit antitumoraktivitaet sowie diese derivate enthaltende zusammensetzungen.
IT1277391B1 (it) Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita
ATE186214T1 (de) Verwendung von rosmanolderivaten zur herstellung von antiradikalischen und/oder antilipoperoxidativen und/oder hepatotropen arzneistoffen
MY118946A (en) Novel intermediates and their use to prepare n, n''- bridged bisindolylmaleimides
MY107258A (en) 1-methoxypyrimidinyl-n-nitrophenyl-1h-1,2,4-triazole-3- sulphonamides, processes for their preparation and their use as herbicides.